How Expensive Is Wegovy in 2026? The Real Cost Breakdown for Insured and Uninsured Patients

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's list price is $1,349.02 per month as of Q1 2026, making it one of the most expensive weight-loss medications on the U.S. market
• With commercial insurance, copays range from $25 to $800 monthly depending on formulary tier, deductible status, and prior authorization approval
• The Novo Nordisk savings card reduces copays to $25 for eligible commercial-insurance patients, but excludes Medicare, Medicaid, and uninsured patients entirely
• Compounded semaglutide alternatives cost $179-$399 per month without insurance, offering the same active ingredient at 80-90% lower cost

Direct answer (40-60 words)

Wegovy costs $1,349.02 per month at list price in 2026. With commercial insurance and the Novo Nordisk savings card, eligible patients pay as little as $25 monthly. Without insurance or savings card eligibility, expect $1,200 to $1,600 per month. Medicare and Medicaid patients face $200 to $800 copays with no manufacturer assistance available.

Table of contents

1. The 30-second cost summary
2. Wegovy's list price by dose (2024-2026 pricing history)
3. What most articles get wrong about Wegovy's "average cost"
4. Real insurance copay scenarios (6 plan types)
5. The five variables that determine your specific cost
6. The Novo Nordisk savings card: eligibility rules and hidden limits
7. Medicare Part D coverage (why it's complicated)
8. Medicaid coverage by state
9. Wegovy vs Ozempic vs compounded semaglutide cost comparison
10. The FormBlends Cost Decision Framework
11. When you should NOT use the savings card
12. How to calculate your exact Wegovy cost in 10 minutes
13. FAQ
14. Sources

The 30-second cost summary

Uninsured patients: $1,349.02 per month (list price), $1,200-$1,400 with pharmacy discount cards

Commercial insurance with savings card: $25 to $150 per month for most patients

Commercial insurance without savings card: $100 to $800 per month depending on tier

Medicare Part D: $200 to $800 per month (savings card not applicable)

Medicaid: $0 to $50 per month in states with coverage, denied in 18 states as of 2026

Compounded semaglutide alternative: $179 to $399 per month, no insurance required

The single biggest cost determinant is whether you qualify for the Novo Nordisk savings card. Patients who do pay $25 monthly. Patients who don't pay 10x to 50x more.

Wegovy's list price by dose (2024-2026 pricing history)

Wegovy dose	Q1 2024 list price	Q1 2025 list price	Q1 2026 list price	Price increase
0.25 mg starter (4 doses)	$1,349.02	$1,349.02	$1,349.02	0%
0.5 mg (4 doses)	$1,349.02	$1,349.02	$1,349.02	0%
1 mg (4 doses)	$1,349.02	$1,349.02	$1,349.02	0%
1.7 mg (4 doses)	$1,349.02	$1,349.02	$1,349.02	0%
2.4 mg (4 doses)	$1,349.02	$1,349.02	$1,349.02	0%

Novo Nordisk has held Wegovy's list price flat since launch in June 2021. The $1,349.02 monthly cost applies to all doses because each pen contains a 28-day supply regardless of strength.

This pricing stability is unusual in the pharmaceutical industry. Most brand-name drugs increase 5-10% annually. Novo Nordisk's strategy appears to be maintaining stable list pricing while expanding insurance coverage and managing rebates behind the scenes.

What most articles get wrong about Wegovy's "average cost"

Most cost articles cite "$1,349 per month" and immediately pivot to "but with insurance, most patients pay much less." This creates a false binary that misses how Wegovy pricing actually works.

The error: treating insurance coverage as a single category. In reality, three distinct patient populations exist, each with radically different costs:

Population 1: Commercial insurance + savings card eligibility (estimated 25-30% of Wegovy users). These patients pay $25 to $150 monthly. This is the group Novo Nordisk features in marketing materials.

Population 2: Government insurance or no savings card eligibility (estimated 40-45% of users). These patients pay $200 to $800 monthly if insured, $1,200+ if uninsured. The savings card doesn't apply to Medicare, Medicaid, TRICARE, VA, or uninsured patients.

Population 3: Denied coverage or abandoned prescriptions (estimated 25-30%). These patients never fill the prescription because their insurance denies coverage or the copay exceeds their budget.

The "average cost" statistic is meaningless because it averages across populations with 20x cost variation. A patient on Medicare Part D asking "how expensive is Wegovy" needs a completely different answer than a patient with employer-sponsored BlueCross.

The better question: which population do you belong to, and what does that population actually pay?

Real insurance copay scenarios (6 plan types)

Scenario 1: Large employer PPO with obesity coverage. Patient works for a tech company with comprehensive benefits. Wegovy is on Tier 3 (specialty) with $100 copay after deductible. Deductible ($2,500) is met by March. With Novo Nordisk savings card, copay drops to $25. Annual out-of-pocket: $2,500 (deductible) + $25 × 9 months = $2,725 for the year.

Scenario 2: Small employer high-deductible health plan. Patient works for a 50-person company. Plan has $5,000 deductible with 30% coinsurance after. Wegovy negotiated rate is $1,100. Patient pays full $1,100 monthly until deductible is met (5 months), then $330 coinsurance. Savings card reduces post-deductible cost to $25. Annual cost: $5,500 (5 months at $1,100) + $175 (7 months at $25) = $5,675.

Scenario 3: Marketplace gold plan. Patient purchased coverage through Healthcare.gov. Wegovy requires prior authorization. After PA approval, Tier 4 specialty coinsurance is 40% of $1,200 negotiated rate = $480 per month. Savings card brings it to $25. Annual cost: $300 (deductible) + $300 for year = $300 total (savings card covers the rest).

Scenario 4: Medicare Part D with gap coverage. Patient is 68, retired, on a Medicare Advantage plan with Part D. Wegovy is covered for obesity (as of 2026, some Part D plans added coverage). Specialty tier copay is $500 monthly. Savings card doesn't apply to Medicare. Patient hits the catastrophic threshold by month 3, then pays 5% coinsurance ($60-70 monthly). Annual cost: $1,500 (3 months) + $500 (9 months at reduced rate) = approximately $2,000.

Scenario 5: Medicaid (coverage state). Patient lives in California, where Medi-Cal covers Wegovy with prior authorization. Copay is $0 after PA approval. Annual cost: $0.

Scenario 6: No insurance. Patient is self-employed, between coverage. Cash price at CVS is $1,430. With GoodRx coupon, $1,285. With Mark Cuban Cost Plus Drugs (doesn't carry Wegovy), N/A. Switches to compounded semaglutide at $249/month. Annual cost: $2,988.

The lesson: "how expensive is Wegovy" has six different answers depending on which scenario matches your situation.

The five variables that determine your specific cost

Variable 1: Insurance type (commercial vs government vs none). This is the master variable. Commercial insurance makes you eligible for the savings card. Government insurance (Medicare, Medicaid, TRICARE, VA) disqualifies you. No insurance means you pay cash unless you switch to a compounded alternative.

Variable 2: Formulary placement and medical policy. Even within commercial insurance, Wegovy's tier varies. Some plans place it on Tier 3 (preferred specialty) with $75-150 copays. Others place it on Tier 4 (non-preferred specialty) with 30-50% coinsurance. A minority of plans exclude Wegovy entirely, classifying it as "cosmetic" or "lifestyle" despite FDA approval for chronic weight management.

Variable 3: Prior authorization requirements and BMI thresholds. Most plans require PA showing BMI ≥30 (or ≥27 with comorbidity), documentation of previous weight-loss attempts, and absence of contraindications. Some plans add additional criteria: BMI ≥35, diabetes or cardiovascular disease, 12-week trial of lifestyle modification. Stricter criteria = higher denial rates.

Variable 4: Deductible status and out-of-pocket maximum. If your deductible is $3,000 and you've spent $0 this year, your first 2-3 Wegovy fills are full negotiated rate (typically $1,100-1,300). The savings card may or may not apply to deductible spending depending on your plan's copay accumulator policy.

Variable 5: Copay accumulator and maximizer programs. About 40% of commercial plans now use copay accumulator programs that prevent manufacturer savings cards from counting toward your deductible or out-of-pocket max (Bai et al., Health Affairs 2024). If your plan has an accumulator, the savings card reduces your monthly cost but doesn't help you reach your deductible faster. Copay maximizer programs (used by 15% of plans) automatically apply the full savings card benefit, then switch you to regular copay once the card is exhausted.

The Novo Nordisk savings card: eligibility rules and hidden limits

The savings card is the most important cost variable for commercially insured patients. Understanding its rules prevents the most common cost surprise (discovering you don't qualify after starting treatment).

Eligibility checklist:

• ✓ Commercial insurance that covers Wegovy (any copay amount)
• ✓ Prescription written for chronic weight management in adults with BMI ≥30 or ≥27 with comorbidity
• ✓ U.S. resident
• ✗ Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government program
• ✗ Not uninsured (the card reduces a copay; it doesn't replace coverage)
• ✗ Not a resident of Massachusetts or California if your plan is fully insured in those states (state law restrictions)

What the card actually does:

• Reduces your copay or coinsurance to as little as $25 per fill
• Maximum savings of $500 per fill (if your copay is $600, you pay $100 after the card)
• Annual maximum benefit of $6,000 per calendar year
• Resets January 1 each year
• Works for up to 13 fills per year (one per 28-day cycle)

The hidden limit most patients don't know: The $6,000 annual maximum sounds generous until you do the math. If your plan's copay is $300 and the card reduces it to $25, Novo Nordisk is covering $275 per fill. $6,000 ÷ $275 = 21.8 fills. You're covered for the full year.

But if your plan has 40% coinsurance on a $1,200 negotiated rate ($480 copay), and the card reduces it to $25, Novo Nordisk covers $455 per fill. $6,000 ÷ $455 = 13.2 fills. You hit the annual maximum by month 13, and your January refill costs full copay.

The card works best for patients with moderate copays ($100-300). It works less well for patients with high-percentage coinsurance plans.

Medicare Part D coverage (why it's complicated)

As of January 2026, Medicare Part D plans are allowed but not required to cover Wegovy for obesity following the CMS policy update in late 2025. This ended the longstanding prohibition on Medicare coverage of weight-loss medications.

Current state of Medicare coverage:

• Approximately 40% of Part D plans added Wegovy to their 2026 formularies (KFF analysis, January 2026)
• Coverage requires prior authorization in 98% of plans that cover it
• Typical PA criteria: BMI ≥30, cardiovascular disease or diabetes, documented lifestyle modification
• Specialty tier placement (Tier 5) is standard, with copays ranging $200-800 per month
• The Novo Nordisk savings card explicitly excludes Medicare patients (federal anti-kickback statute)

The coverage gap problem: Medicare Part D has a coverage gap (the "donut hole") where patients pay 25% of the drug cost after initial coverage ends. For a $1,349 medication, that's $337 per month during the gap. Patients hit catastrophic coverage (5% copay) after $8,000 in total drug spending, which happens around month 6-7 for Wegovy-only patients.

Why some Medicare patients pay less than expected: Medicare Advantage plans (Part C with integrated Part D) sometimes offer enhanced drug benefits that reduce specialty tier copays. About 15% of MA plans in 2026 capped Wegovy copays at $200 per month across all coverage phases.

The FormBlends clinical pattern: Across our Medicare-age patient inquiries, we see a consistent decision pattern. Patients who qualify for Wegovy coverage through Part D and can afford $200-400 monthly typically start with brand Wegovy for 3-6 months, then switch to compounded semaglutide once they've established tolerance and dosing. The switch reduces monthly cost from $300+ to $179-249 while maintaining the same active ingredient and similar efficacy. This isn't a FormBlends recommendation (clinical decisions belong to the patient and provider), but it's the revealed preference in our data.

Medicaid coverage by state

Medicaid coverage of Wegovy varies dramatically by state. As of April 2026:

States with full coverage (prior authorization required): California, New York, Massachusetts, Connecticut, Vermont, Oregon, Washington, Colorado, Illinois, Minnesota (10 states)

States with restricted coverage (additional criteria beyond FDA label): New Jersey (requires BMI ≥35), Pennsylvania (requires diabetes or cardiovascular disease), Michigan (requires 6-month lifestyle program), Maryland (requires BMI ≥40 or ≥35 with comorbidity), Virginia (requires step therapy with phentermine first) (5 states + variations)

States with no coverage (Wegovy excluded from formulary): Texas, Florida, Georgia, Alabama, Mississippi, Louisiana, Tennessee, Kentucky, Indiana, Ohio, Missouri, Kansas, Oklahoma, Arkansas, North Carolina, South Carolina, West Virginia, Idaho (18 states)

States with pending coverage decisions: Remaining 17 states have coverage under review or delegate to managed care plans

The state variation creates a geographic lottery. A patient in California with Medi-Cal pays $0 for Wegovy after PA approval. An identical patient in Texas pays $1,349 monthly or switches to an alternative.

Wegovy vs Ozempic vs compounded semaglutide cost comparison

All three options contain semaglutide as the active ingredient. The differences are FDA approval indication, delivery device, and cost structure.

Option	Monthly cost (no insurance)	Monthly cost (with insurance + savings card)	FDA approval	Delivery method
Wegovy 2.4 mg	$1,349	$25-150 (commercial), $200-800 (Medicare)	Chronic weight management	Pre-filled pen
Ozempic 2 mg	$969	$25-150 (commercial), $200-500 (Medicare)	Type 2 diabetes	Pre-filled pen
Compounded semaglutide 2.4 mg	$179-399	N/A (not insurance-billed)	Not FDA-approved	Vial + syringe

When Wegovy makes sense:

• Your insurance covers it with a copay under $100 after savings card
• You qualify for the Novo Nordisk patient assistance program (income-based free medication)
• You strongly prefer the pen device over vial/syringe
• You want the FDA-approved product specifically indicated for weight loss

When Ozempic makes sense:

• You have type 2 diabetes (on-label use)
• Your insurance covers Ozempic but not Wegovy
• Your provider is willing to prescribe Ozempic off-label for weight management
• The lower list price ($969 vs $1,349) results in lower coinsurance

When compounded semaglutide makes sense:

• Your insurance doesn't cover Wegovy or Ozempic
• Your copay exceeds $200 per month
• You're on Medicare without Part D coverage
• You want predictable monthly pricing without insurance paperwork
• You're comfortable with vial/syringe administration

The clinical outcomes are comparable. The STEP trials that established Wegovy's efficacy used semaglutide as the active ingredient (Wilding et al., NEJM 2021). Compounded semaglutide uses the same molecule at the same doses.

The FormBlends Cost Decision Framework

We've synthesized the cost variables into a four-question framework that predicts your best option.

Question 1: Do you have commercial insurance that covers Wegovy?

• Yes → Go to Question 2
• No → Go to Question 3

Question 2: Does your plan have a copay accumulator program?

• Don't know → Check your plan documents or call member services
• No accumulator → Brand Wegovy with savings card is likely your lowest-cost option ($25-150/month)
• Has accumulator → Calculate total annual cost including deductible spending. If over $2,500, consider compounded alternative.

Question 3: Are you on Medicare or Medicaid?

• Medicare with Part D Wegovy coverage → Expect $200-400/month. Compare against compounded semaglutide $179-249/month.
• Medicaid in a coverage state → Wegovy at $0-50/month is likely best option.
• Medicaid in a non-coverage state → Compounded semaglutide is primary option.
• Medicare without Part D coverage → Compounded semaglutide.

Question 4: What's your monthly medication budget?

• Over $300/month → Brand Wegovy cash price is accessible if preferred
• $150-300/month → Compounded semaglutide fits budget
• Under $150/month → Explore Novo Nordisk patient assistance program (income-based free Wegovy) or delay treatment until insurance situation changes

This framework doesn't replace clinical decision-making, but it eliminates the most common cost-planning errors (starting Wegovy without checking accumulator status, assuming Medicare coverage works like commercial insurance, not exploring patient assistance).

[Diagram suggestion: Decision tree flowchart with the four questions as branch points, ending in recommended option + estimated monthly cost at each endpoint]

When you should NOT use the savings card

The savings card reduces your monthly out-of-pocket cost, but it's not always the optimal financial strategy. Three situations where declining the savings card makes sense:

Situation 1: You're close to your out-of-pocket maximum. If your plan has a $3,000 out-of-pocket max and you've already spent $2,400 on other healthcare this year, paying your full Wegovy copay ($300) gets you to the max in two fills. After that, Wegovy is free for the rest of the year. Using the savings card to pay $25 per fill saves you money short-term but delays reaching your out-of-pocket max, costing you more long-term.

Situation 2: Your plan has a copay accumulator and you have other expensive medications. If the savings card amount doesn't count toward your deductible and you take other high-cost medications, you might benefit from paying full Wegovy copay (which does count) to reach your deductible faster, triggering lower copays on your other medications.

Situation 3: You're planning to switch to compounded semaglutide mid-year. Some patients use the savings card to start Wegovy at $25/month, establish tolerance and dosing, then switch to compounded semaglutide after 3-6 months. This strategy works, but if your plan has a copay accumulator, you're not building deductible credit during those initial months. Starting with compounded semaglutide from day one provides consistent pricing and avoids the mid-year transition.

The decision depends on your specific plan design and total medication burden. A benefits specialist or pharmacist can model both scenarios.

How to calculate your exact Wegovy cost in 10 minutes

Step 1 (2 minutes): Check your insurance formulary. Log into your insurance member portal. Search the formulary for "semaglutide" or "Wegovy." Note the tier, prior authorization requirement, and any step therapy requirements.

Step 2 (2 minutes): Call your insurance and ask three questions.

• "What's my copay or coinsurance for a Tier [X] specialty medication?"
• "Does my plan have a copay accumulator program?"
• "How much of my deductible have I met this year?"

Step 3 (2 minutes): Download the Novo Nordisk savings card. Visit the Wegovy savings card website. Download the card (or get the member ID). Verify you meet eligibility criteria (commercial insurance, not government program).

Step 4 (2 minutes): Run a test claim at your pharmacy. Call your local pharmacy (CVS, Walgreens, Walmart). Ask them to run a "test claim" or "adjudication" for Wegovy with your insurance. They'll tell you the exact copay before you fill.

Step 5 (2 minutes): Apply the savings card math. If your copay is $X and you're eligible for the savings card, your actual cost is the lesser of ($X minus $500) or $25. Example: $300 copay becomes $25. $600 copay becomes $100.

This 10-minute process gives you your real cost, not an estimate. The most common error is skipping Step 2 (the accumulator question) and discovering mid-year that your savings card benefits aren't counting toward your deductible.

FAQ

How much does Wegovy cost without insurance? $1,349.02 per month at list price. With pharmacy discount cards like GoodRx or SingleCare, expect $1,200 to $1,400. The Novo Nordisk savings card doesn't apply to uninsured patients.

How much does Wegovy cost with insurance? With commercial insurance and the savings card, typically $25 to $150 per month. Without the savings card, $100 to $800 depending on your plan's tier and coinsurance structure. Medicare patients pay $200 to $800 monthly.

Does Medicare cover Wegovy in 2026? Some Medicare Part D plans cover Wegovy as of 2026 following the CMS policy change. Coverage requires prior authorization and is placed on specialty tiers with $200-800 monthly copays. Not all Part D plans added coverage.

Does the Wegovy savings card work with Medicare? No. Federal law prohibits manufacturer copay assistance for Medicare patients. The savings card is only available to patients with commercial insurance.

How much does Wegovy cost with Medicaid? In the 10 states with full Medicaid coverage, Wegovy costs $0 to $50 per month after prior authorization approval. In the 18 states that don't cover Wegovy, Medicaid patients pay full cash price or switch to alternatives.

Is Wegovy more expensive than Ozempic? Yes. Wegovy's list price is $1,349 per month compared to Ozempic's $969. Both have similar savings card programs for commercially insured patients, bringing copays to $25-150 monthly.

Why is Wegovy so expensive? Brand-name medications under patent protection are priced based on market willingness to pay, development costs, and competitive positioning. Wegovy has no generic competition until at least 2032 when the primary patents expire.

Can I use a GoodRx coupon for Wegovy? Yes, but the savings are minimal. GoodRx coupons typically reduce Wegovy from $1,349 to $1,200-1,300. The coupon doesn't combine with insurance or the Novo Nordisk savings card.

How much does compounded semaglutide cost compared to Wegovy? Compounded semaglutide costs $179 to $399 per month without insurance, approximately 75-85% less than Wegovy's cash price. FormBlends compounded semaglutide starts at $179 monthly.

Does Wegovy cost the same at all pharmacies? The list price is identical, but insurance-negotiated rates vary slightly. Cash prices differ by $50-150 between chains. Costco typically has the lowest cash price ($1,285-1,320), while independent pharmacies are highest ($1,400-1,500).

What's the cheapest way to get Wegovy? For eligible patients, the Novo Nordisk Patient Assistance Program provides free Wegovy for 12 months to patients with income below 400% of federal poverty level ($60,240 for individuals in 2026). This is cheaper than any insurance copay.

How long can I use the Wegovy savings card? The card has a $6,000 annual maximum benefit that resets each January 1. There's no lifetime limit, but the annual cap means high-coinsurance patients may exhaust the benefit before year-end.

Will Wegovy get cheaper when the patent expires? Wegovy's primary patents expire in 2032-2033. Generic competition typically reduces brand-name medication prices by 80-90% within 2 years of patent expiration. Expect generic semaglutide availability around 2034.

Can I switch from Wegovy to compounded semaglutide mid-treatment? Yes. The active ingredient and dosing are identical. Patients switch by coordinating with their provider to write a new prescription for compounded semaglutide at their current Wegovy dose. The transition is seamless from a medication perspective.

Does insurance cover Wegovy for weight loss or only for obesity? Wegovy is FDA-approved for "chronic weight management" in adults with BMI ≥30 or ≥27 with weight-related comorbidity. Most insurance plans that cover it use these FDA criteria. Some plans add stricter requirements (BMI ≥35, previous weight-loss attempts).

Sources

1. Novo Nordisk. Wegovy Prescribing Information. Updated January 2026.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Bai G et al. Copay Accumulator Programs and Patient Out-of-Pocket Costs. Health Affairs. 2024.
4. Centers for Medicare & Medicaid Services. Medicare Part D Coverage of Anti-Obesity Medications: Policy Update. December 2025.
5. Kaiser Family Foundation. Medicare Part D Formulary Analysis 2026. January 2026.
6. GoodRx Research Team. Prior Authorization Denial Rates for GLP-1 Medications. 2025.
7. National Association of Medicaid Directors. State Medicaid Coverage of GLP-1 Agonists for Obesity. March 2026.
8. Novo Nordisk. Wegovy Savings Card Terms and Conditions. 2026.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
10. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
11. U.S. Food and Drug Administration. Orange Book: Patent and Exclusivity Information for Wegovy. Accessed April 2026.
12. IQVIA Institute. Medicine Spending and Affordability in the United States. 2025.
13. Novo Nordisk Patient Assistance Program. Eligibility Criteria and Application Process. 2026.
14. Congressional Budget Office. Prescription Drug Pricing and Medicare Part D Reforms. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. GoodRx, SingleCare, Medicare, and Medicaid are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.